Clinical Study on the Intervention of Xuesaitong Soft Capsules in Post-Intervention Patients with Acute Coronary Syndrome and Clinical Research Protocol

Inclusion Criteria:

1. Patients diagnosed with acute ST-segment elevation myocardial infarction, acutenon-ST-segment elevation myocardial infarction, or unstable angina according toWestern medical standards. Inclusion Criteria.

2. Within 4 weeks post-PCI.

3. Aged between 18 and 80 years, both male and female.

4. Voluntarily participating in the clinical trial, having signed the informed consentform.

Exclusion Criteria:

1. Uncontrolled hypertension after medication (systolic BP >180mmHg or diastolic BP > 110mmHg).

2. Increased bleeding risk: history of hemorrhagic stroke; intracranial aneurysm; majortrauma or surgery within the past month (including Exclusion Criteria bypasssurgery); active bleeding disorders.

3. History of gastrointestinal ulcers or significant gastrointestinal bleeding.

4. Severe organic heart disease, such as LVEF < 35% or NYHA/Killip heart function gradeIV.

5. History of malignant arrhythmias within the past year (arrhythmias affectinghemodynamics requiring medication or electrical cardioversion, or requiring CPR),congenital heart disease, or malignant tumors.

6. Severe liver or kidney dysfunction: ALT or AST ≥ 3×ULN, TBIL≥ 2×ULN, or creatinineclearance < 30ml/min.

7. Pregnant or lactating women.

8. Recent blood donation or significant blood loss within the past 3 months (≥400ml).

9. History of alcohol abuse (≥28 standard units/week for males, ≥21 standard units/weekfor females) or frequent alcohol consumption in the past 6 months (≥14 standardunits/week).

10. History of drug abuse or dependence within the past year. Participation in otherclinical trials and taking trial drugs within the past 3 months.

11. Allergy or intolerance to aspirin or P2Y12 receptor inhibitors.

12. Allergy to any components of the trial drug.

13. Other conditions deemed inappropriate for participation by the nvestigator